trans-sodium-crocetinate and Respiratory-Distress-Syndrome

trans-sodium-crocetinate has been researched along with Respiratory-Distress-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for trans-sodium-crocetinate and Respiratory-Distress-Syndrome

Article	Year
Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation. Journal of controlled release : official journal of the Controlled Release Society, 2021, 08-10, Volume: 336 Current therapeutic treatments improving the impaired transportation of oxygen in acute respiratory distress syndrome (ARDS) have been found to be relevant and beneficial for the therapeutic treatment of COVID-19 patients suffering from severe respiratory complications. Hence, we report the preclinical and the preliminary results of the Phase I/II clinical trial of LEAF-4L6715, a liposomal nanocarrier encapsulating the kosmotropic agent trans-crocetin (TC), which, once injected, enhance the oxygenation of vascular tissue and therefore has the potential to improve the clinical outcomes of ARDS and COVID-19 in severely impacted patients. We demonstrated that the liposomal formulation enabled to increase from 30 min to 48 h the reoxygenation properties of free TCs in vitro in endothelial cells, but also to improve the half-life of TC by 6-fold in healthy mice. Furthermore, we identified 25 mg/kg as the maximum tolerated dose in mice. This determined concentration led to the validation of the therapeutic efficacy of LEAF-4 L6715 in a sepsis mouse model. Finally, we report the preliminary outcomes of an open-label multicenter Phase I/II clinical trial (EudraCT 2020-001393-30; NCT04378920), which was aimed to define the appropriate schedule and dosage of LEAF-4L6715 and to confirm its tolerability profile and preliminary clinical activity in COVID-19 patients treated in intensive care unit. Topics: Animals; Carotenoids; COVID-19; Endothelial Cells; Humans; Mice; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Vitamin A	2021
The effect of trans sodium crocetinate (TSC) in a rat oleic acid model of acute lung injury. Pulmonary pharmacology & therapeutics, 2005, Volume: 18, Issue:3 Trans sodium crocetinate is a novel drug, which has been shown previously to increase whole-body oxygen consumption during hemorrhagic shock. TSC has been suggested to work by increasing the diffusion rate of oxygen through plasma rather than on a specific symptom of hemorrhagic shock and has been suggested as a general treatment for hypoxemia. Thus, it might also be beneficial for treating respiratory insufficiencies. This study employed an oleic acid model of acute lung injury to determine if TSC could increase arterial PO2 in that model. Topics: Animals; Antioxidants; Carotenoids; Male; Oleic Acid; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Vitamin A	2005

Article

Year

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.

Journal of controlled release : official journal of the Controlled Release Society, 2021, 08-10, Volume: 336

Current therapeutic treatments improving the impaired transportation of oxygen in acute respiratory distress syndrome (ARDS) have been found to be relevant and beneficial for the therapeutic treatment of COVID-19 patients suffering from severe respiratory complications. Hence, we report the preclinical and the preliminary results of the Phase I/II clinical trial of LEAF-4L6715, a liposomal nanocarrier encapsulating the kosmotropic agent trans-crocetin (TC), which, once injected, enhance the oxygenation of vascular tissue and therefore has the potential to improve the clinical outcomes of ARDS and COVID-19 in severely impacted patients. We demonstrated that the liposomal formulation enabled to increase from 30 min to 48 h the reoxygenation properties of free TCs in vitro in endothelial cells, but also to improve the half-life of TC by 6-fold in healthy mice. Furthermore, we identified 25 mg/kg as the maximum tolerated dose in mice. This determined concentration led to the validation of the therapeutic efficacy of LEAF-4 L6715 in a sepsis mouse model. Finally, we report the preliminary outcomes of an open-label multicenter Phase I/II clinical trial (EudraCT 2020-001393-30; NCT04378920), which was aimed to define the appropriate schedule and dosage of LEAF-4L6715 and to confirm its tolerability profile and preliminary clinical activity in COVID-19 patients treated in intensive care unit.

Topics: Animals; Carotenoids; COVID-19; Endothelial Cells; Humans; Mice; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Vitamin A

2021

The effect of trans sodium crocetinate (TSC) in a rat oleic acid model of acute lung injury.

Pulmonary pharmacology & therapeutics, 2005, Volume: 18, Issue:3

Trans sodium crocetinate is a novel drug, which has been shown previously to increase whole-body oxygen consumption during hemorrhagic shock. TSC has been suggested to work by increasing the diffusion rate of oxygen through plasma rather than on a specific symptom of hemorrhagic shock and has been suggested as a general treatment for hypoxemia. Thus, it might also be beneficial for treating respiratory insufficiencies. This study employed an oleic acid model of acute lung injury to determine if TSC could increase arterial PO2 in that model.

Topics: Animals; Antioxidants; Carotenoids; Male; Oleic Acid; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Vitamin A

2005